Drug intelligence / Profile preview

INB-300

Development stage: Preclinical
Lead developer: IN8bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

INB-300 is an nsCAR (non-signaling Chimeric Antigen Receptor) platform developed by IN8bio. It is designed to target CD33 and CD123, which are cell surface markers often found on cancer cells. The development of INB-300 is based on an exclusive worldwide license from The UAB Research Foundation for immunotherapy-related patents covering gamma-delta T cells, CAR-T cells, and combination treatments. Preclinical data demonstrating proof-of-concept for this platform is planned for presentation in the first half of 2024.

Other names: chlorotoxin-CAR gamma-delta T cellsCLTX-CAR gamma-delta T cellsDeltEx DRI CAR-T

Targets

CD33 (Myeloid cell surface antigen CD33)IL3RA (Interleukin 3 Receptor)

Beyond the preview

Go deeper on INB-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INB-300.

Explore the full profile